Cancer and Immune Response: Old and New Evidence for Future Challenges.
Autor: De la Cruz-Merino, Luis; Grande-Pulido, E.; Albero-Tamarit, Ana; Codes-Manuel de Villena, Manuel Eduardo
Resumen: Cancer may occur as a result of abnormal host immune system tolerance. Recent studies have confirmed the occurrence of spontaneous and induced
antitumor immune responses expressed as the presence of tumor-infiltrating T cells in the tumor microenvironment in some cancer models. This finding has
been recognized as a good prognostic factor in several
types of tumors. Some chemotherapy agents, such as
anthracyclines and gemcitabine, are effective boosters of the immune response through tumor-specific
antigen overexpression after apoptotic tumor cell destruction. Other strategies, such as GM-CSF or interleukin-2, are pursued to increase immune cell
availability in the tumor vicinity, and thus improve
both antigen presentation and T-cell activation and
proliferation. In addition, cytotoxic T lymphocyte antigen 4 – blocking monoclonal antibodies enhance immune activity by prolonging T-cell activation.
Strategies to stimulate the dormant immune system
against tumors are varied and warrant further investigation of their applications to cancer therapy in the
future.
Identificador universal: https://hdl.handle.net/10641/3802
Fecha: 2008
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |
Este ítem aparece en la(s) siguiente(s) colección(ones)
- MEDICINA [816]